Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m (1) TP).

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly ...

Research on mRNA vaccines have been under fire in the post-pandemic age, but these immunotherapies are showing promise in the ...

MIT researchers have developed an experimental mRNA-based therapy that restored key immune functions lost with age in mice.

A trio of mRNA molecules could help guard against the harmful effects of aging on immune cells, a study in mice finds. A new ...

An analysis of ongoing trials suggests that mRNA cancer vaccines have the potential to deliver health benefits worth $75 ...